Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sales Of BioMarin’s Hemophilia Gene Therapy Move At Glacial Pace

Three Patients Treated In 2023

Feb 23 2024

• By Alaric DeArment

• Source: Shutterstock

Related Content

Its Gene Therapy Roctavian Finally Approved With $2.9m Price, BioMarin Aims To Prove Doubters Wrong

Jun 30 2023

€1.5m Price Tag Could Spell EU Success For BioMarin’s Hemophilia Gene Therapy

Aug 25 2022

Related Companies

BioMarin Pharmaceutical Inc.

Additional Topics

Sales & Earnings Strategy Gene Therapy Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.